Catastrophic antiphospholipid syndrome (CAPS) is a potentially lethal disease that presents with rapidly progressive multiple organ thromboses. Anticoagulation, corticosteroids, intravenous immunoglobulin, and plasma exchange are the most commonly used treatments for CAPS patients. However, the high mortality despite these medications necessitates new treatment strategies. Following a brief review of current diagnostic and management strategies, we discuss the candidate therapies, i.e., hydroxychloroquine, rituximab, eculizumab, sirolimus, and defibrotide, that can be considered in CAPS patients refractory to traditional treatment.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Miyakis S, Lockshin MD, Atsumi T. 1.  et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4:295–306 [Google Scholar]
  2. Erkan D, Lockshin MD. 2.  2010. Non-criteria manifestations of antiphospholipid syndrome. Lupus 19:424–27 [Google Scholar]
  3. Asherson RA. 3.  1992. The catastrophic antiphospholipid syndrome. J. Rheumatol. 19:508–12 [Google Scholar]
  4. Piette JC, Cervera R, Levy RA. 4.  et al. 2003. The catastrophic antiphospholipid syndrome—Asherson's syndrome. Ann. Med. Interne (Paris) 154195–96 [Google Scholar]
  5. Asherson RA, Cervera R, de Groot PG. 5.  et al. 2003. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530–34 [Google Scholar]
  6. Aguiar CL, Erkan D. 6.  2013. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther. Adv. Musculoskelet. Dis. 5:305–14 [Google Scholar]
  7. Cervera R, Rodriguez-Pinto I, Colafrancesco S. 7.  et al. 2014. 14th International Congress on Antiphospholipid Antibodies: task force report on catastrophic antiphospholipid syndrome. Autoimmun. Rev. 13:699–707 [Google Scholar]
  8. Erkan D, Espinosa G, Cervera R. 8.  2010. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun. Rev. 10:74–79 [Google Scholar]
  9. Ortel TL, Erkan D, Kitchens CS. 9.  2015. How I treat catastrophic thrombotic syndromes. Blood 126:1285–93 [Google Scholar]
  10. Ortel TL, Kitchens CS, Erkan D. 10.  et al. 2012. Clinical causes and treatment of the thrombotic storm. Expert Rev. Hematol. 5:653–59 [Google Scholar]
  11. Cervera R. 11.  2012. CAPS registry. Lupus 21:755–57 [Google Scholar]
  12. Girardi G, Redecha P, Salmon JE. 12.  2004. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10:1222–26 [Google Scholar]
  13. Asherson RA, Cervera R, Merrill JT, Erkan D. 13.  2008. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin. Thromb. Hemost. 34:256–66 [Google Scholar]
  14. Erkan D, Cervera R, Asherson RA. 14.  2003. Catastrophic antiphospholipid syndrome: Where do we stand?. Arthritis Rheumatol 48:3320–27 [Google Scholar]
  15. Bayraktar UD, Erkan D, Bucciarelli S. 15.  et al. 2007. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J. Rheumatol. 34:346–52 [Google Scholar]
  16. Erkan D, Aguiar CL, Andrade D. 16.  et al. 2014. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun. Rev. 13:685–96 [Google Scholar]
  17. Cervera R, Asherson RA. 17.  2004. Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the ‘catastrophic’ antiphospholipid syndrome. APLAR J. Rheumatol. 7:254–62 [Google Scholar]
  18. Erkan D, Salmon JE. 18.  2016. The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome. Turk. J. Haematol. 33:1–7 [Google Scholar]
  19. Edwards MH, Pierangeli S, Liu X. 19.  et al. 1997. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96:4380–84 [Google Scholar]
  20. Rand JH, Wu XX, Quinn AS. 20.  et al. 2008. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 112:1687–95 [Google Scholar]
  21. Rand JH, Wu XX, Quinn AS. 21.  et al. 2010. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 115:2292–99 [Google Scholar]
  22. Wu XX, Guller S, Rand JH. 22.  2011. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am. J. Obstet. Gynecol. 205:576.e7–14 [Google Scholar]
  23. Sacre K, Criswell LA, McCune JM. 23.  2012. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 14:R155 [Google Scholar]
  24. Johnson R, Charnley J. 24.  1979. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty. Clin. Orthop. Relat. Res. 144:174–77 [Google Scholar]
  25. Wallace DJ. 25.  1987. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?. Arthritis Rheumatol 30:1435–36 [Google Scholar]
  26. Petri M, Law G, Fang H, Magder L. 26.  2013. Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, but only in antiphospholipid positive patients. Proc. Int. Congr. Antiphospholipid Antibodies, 14th, Rio de Janeiro, Brazil18–21 [Google Scholar]
  27. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. 27.  2009. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheumatol 61:29–36 [Google Scholar]
  28. Buch MH, Smolen JS, Betteridge N. 28.  et al. 2011. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70:909–20 [Google Scholar]
  29. Khattri S, Zandman-Goddard G, Peeva E. 29.  2012. B-cell directed therapies in antiphospholipid antibody syndrome—new directions based on murine and human data. Autoimmun. Rev. 11:717–22 [Google Scholar]
  30. Youinou P, Renaudineau Y. 30.  2004. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. Thromb. Res. 114:363–69 [Google Scholar]
  31. Kahn P, Ramanujam M, Bethunaickan R. 31.  et al. 2008. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheumatol 58:2824–34 [Google Scholar]
  32. Akkerman A, Huang W, Wang X. 32.  et al. 2004. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity 37:445–51 [Google Scholar]
  33. Erdozain JG, Ruiz-Irastorza G, Egurbide MV, Aguirre C. 33.  2004. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 89:Ecr34 [Google Scholar]
  34. Erre GL, Pardini S, Faedda R, Passiu G. 34.  2008. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 17:50–55 [Google Scholar]
  35. Kumar D, Roubey RA. 35.  2010. Use of rituximab in the antiphospholipid syndrome. Curr. Rheumatol. Rep. 12:40–44 [Google Scholar]
  36. Rubenstein E, Arkfeld DG, Metyas S. 36.  et al. 2006. Rituximab treatment for resistant antiphospholipid syndrome. J. Rheumatol. 33:355–57 [Google Scholar]
  37. Tenedios F, Erkan D, Lockshin M. 37.  2005. Rituximab in the primary antiphospholipid syndrome (PAPS). Arthritis Rheumatol 52:4078 [Google Scholar]
  38. Aguiar CL, Erkan D. 38.  2013. The effect of rituximab on the antiphospholipid antibody profile. Proc. APLA-LACA (Abstr.), Int. Congr. Antiphospholipid Antibodies, 14th, and Latin Am. Congr. Autoimmun., 4th, Sep. 18–21, Rio de Janeiro, Brazil
  39. Ames PR, Tommasino C, Fossati G. 39.  et al. 2007. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann. Hematol. 86:227–28 [Google Scholar]
  40. Tommasino C, Fossati G, Saulino A. 40.  et al. 2004. Short-term lack of efficacy of rituximab in a thrombocytopaenic patient with primary antiphospholipid syndrome. Thromb. Res. 114:652 (Abstr.) [Google Scholar]
  41. Sciascia S, Naretto C, Rossi D. 41.  et al. 2011. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 20:1106–8 [Google Scholar]
  42. Trappe R, Loew A, Thuss-Patience P. 42.  et al. 2006. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann. Hematol. 85:134–35 [Google Scholar]
  43. Costa R, Fazal S, Kaplan RB. 43.  et al. 2013. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin. Rheumatol. 32:Suppl. 1S79–S82 [Google Scholar]
  44. Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A. 44.  2011. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif. Organs 35:420–25 [Google Scholar]
  45. Ehresmann SAD, Shinada S. 45.  et al. 2004. A novel therapeutic approach for catastrophic antiphospholipid syndrome (CAPS) when conventional therapy with anticoagulants and steroids were unsuccessful. Ann. Rheum. Dis. 64:Suppl.FR10278 (Abstr.) [Google Scholar]
  46. Berman H, Rodriguez-Pinto I, Cervera R. 46.  et al. 2013. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun. Rev. 12:1085–90 [Google Scholar]
  47. Erkan D, Vega J, Ramon G. 47.  et al. 2013. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheumatol 65:464–71 [Google Scholar]
  48. Canaud G, Kamar N, Anglicheau D. 48.  et al. 2013. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am. J. Transplant. 13:2179–85 [Google Scholar]
  49. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. 49.  2007. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109:422–30 [Google Scholar]
  50. Peerschke EI, Yin W, Ghebrehiwet B. 50.  2010. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol. Immunol. 47:2170–75 [Google Scholar]
  51. Canaud G, Bienaime F, Tabarin F. 51.  et al. 2014. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N. Engl. J. Med. 371:303–12 [Google Scholar]
  52. Pierangeli SS, Girardi G, Vega-Ostertag M. 52.  et al. 2005. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheumatol 52:2120–24 [Google Scholar]
  53. Oku K, Amengual O, Atsumi T. 53.  2012. Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome. Eur. J. Clin. Investig. 42:1126–35 [Google Scholar]
  54. Devreese KM, Hoylaerts MF. 54.  2010. Is there an association between complement activation and antiphospholipid antibody-related thrombosis?. Thromb. Haemost. 104:1279–81 [Google Scholar]
  55. Zikos TA, Sokolove J, Ahuja N, Berube C. 55.  2015. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J. Clin. Rheumatol. 21:311–13 [Google Scholar]
  56. Sehgal SN. 56.  2003. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant. Proc. 35:7s–14s [Google Scholar]
  57. Rubbia-Brandt L. 57.  2010. Sinusoidal obstruction syndrome. Clin. Liver Dis. 14:651–68 [Google Scholar]
  58. Pescador R, Porta R, Ferro L. 58.  1996. An integrated view of the activities of defibrotide. Semin. Thromb. Hemost. 22:Suppl. 171–75 [Google Scholar]
  59. Richardson PG, Elias AD, Krishnan A. 59.  et al. 1998. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 92:737–44 [Google Scholar]
  60. Falanga A, Vignoli A, Marchetti M, Barbui T. 60.  2003. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 17:1636–42 [Google Scholar]
  61. Burcoglu-O'Ral A, Erkan D, Asherson R. 61.  2002. Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J. Rheumatol. 29:2006–11 [Google Scholar]
  62. Wilson WA, Gharavi AE, Koike T. 62.  et al. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheumatol 42:1309–11 [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error